COMPUGEN LTD (CGEN) Form 6-K — Nov 9, 2026
Compugen reported Q3 2026 results with revenue of approximately $3.8 million (up from $1.9 million a year ago) and a net loss of approximately $5.8 million, or $0.06 per share, versus a $7.0 million loss in Q3 2025. The company said its MAIA-ovarian trial of COM701 in relapsed platinum-sensitive ovarian cancer is now fully enrolled with 62 patients, and results are on track to be reported by the end of Q1 2027. Partner AstraZeneca's Phase 3 high-level results for rilvegostomig from ARTEMIDE-Biliary01 are anticipated in the second half of 2027.
Key figures
- Revenue
- 3821000
- Revenue Yoy
- approximately +102% (vs ~$1.9M in Q3 2025)
- Cash Position
- 117500000
- Total assets
- 129534000
- Ga expenses q3 2026
- 2275000
- Rd expenses q3 2026
- 5842000
- Maia ovarian patients
- 62
- Gilead received to date
- $90 million
- Total shareholders equity
- 83363000
- Gilead remaining milestones
- up to $758 million
- Weighted avg shares q3 2026
- 94768232
- Artemide biliary01 participants
- 760
- Astra Zeneca remaining milestones
- up to $195 million
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.